Analysis of the incidence and influencing factors of hyponatremia before 131I treatment of differentiated thyroid carcinoma

Table 1 Clinical data of the patients with hyponatremia before ¹³¹I treatment

Patients	Age (yr)	Gender	Pre-operation sodium (mmol/L)	Pre-131I therapy sodium (mmol/L)	Potentially hyponatremia-inducing drugs	Potentially hyponatremia-inducing comorbidities
1	75	Male	138	134	Diuretic, ACEI	DM, adenocarcinoma of lung
2	71	Male	140	135	Diuretic, ARB	None
3	71	Male	140	133	None	None
4	64	Male	141	134	Diuretic	None
5	64	Male	141	135	None	None
6	64	Male	144	133	None	None
7	63	Male	136	134	Diuretic, ACEI	None
8	53	Male	140	135	None	DM
9	52	Male	138	135	None	DM, coronary heart disease
10	47	Male	144	135	None	None
11	45	Male	138	135	None	Adrenocortical hypofunction
12	38	Male	136	131	None	None
13	31	Male	136	128	None	DM
14	69	Female	140	129	None	RI, CHD, old cerebral infarction
15	49	Female	136	135	None	None
16	47	Female	142	135	None	None
17	42	Female	140	135	None	None
18	42	Female	140	134	None	None
19	41	Female	137	132	None	DM, diabetic nephropathy
20	35	Female	145	135	None	None
21	35	Female	138	134	None	None
22	33	Female	142	135	None	Chronic hepatitis B
23	32	Female	138	133	None	None

DM: Diabetes mellitus; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; CHD: Coronary heart disease; RI: Renal insufficiency.